All Posts
Study: Biochemical failure is not a surrogate end point for overall survival in recurrent prostate cancer.
28 Jun, 2022 | 10:32h | UTCBiochemical Failure Is Not a Surrogate End Point for Overall Survival in Recurrent Prostate Cancer: Analysis of NRG Oncology/RTOG 9601 – Journal of Clinical Oncology (link to abstract – $ for full-text)
RCT: Comparison of collaborative goal setting with enhanced education for managing diabetes-associated distress and Glycated hemoglobin levels.
28 Jun, 2022 | 10:33h | UTC
Commentary on Twitter
https://twitter.com/JAMANetworkOpen/status/1521882849409916928
Phase 2 RCT: Durvalumab plus Olaparib in previously untreated, platinum-ineligible patients with metastatic urothelial carcinoma.
28 Jun, 2022 | 10:31h | UTCDurvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU) – Journal of Clinical Oncology (link to abstract – $ for full-text)
Commentary from the author on Twitter
Results from Durva+/-Olaparib in 1L platinum ineligible mUC published in JCO. No benefit in ITT, but prolonged PFS in HRRm patients. Worthy of further investigation. Tough trial to do, made possible by great international team. @MSKCancerCenter @JCO_ASCO https://t.co/9hQNYoR5OE pic.twitter.com/bz1wTAXp7K
— Jonathan Rosenberg MD (@DrRosenbergMSK) June 24, 2022
Infertility, recurrent pregnancy loss, and risk of stroke: pooled analysis of individual patient data of 618 851 women.
27 Jun, 2022 | 11:59h | UTCNews Release: Infertility and pregnancy loss may increase women’s risk of stroke – BMJ Newsroom
Commentary on Twitter
Infertility and pregnancy loss are associated with an increased risk of non-fatal and fatal stroke in later life, finds study.
Early monitoring of women who have experienced miscarriage or stillbirth could lower the risk, the researchers suggest https://t.co/fYrNfpz6fC
— The BMJ (@bmj_latest) June 24, 2022
Systematic Review: Antibiotics for uncomplicated diverticulitis.
27 Jun, 2022 | 11:56h | UTCAntibiotics for uncomplicated diverticulitis – Cochrane Library
Summary: Antibiotics for uncomplicated diverticulitis – Cochrane Library
Related:
Efficacy and Safety of Non-Antibiotic Outpatient Treatment in Mild Acute Diverticulitis (DINAMO-study): A Multicentre, Randomised, Open-Label, Non-Inferiority Trial – Annals of Surgery (link to abstract – $ for full-text)
Elective surgical management of diverticulitis – Current Problems in Surgery
Management of Colonic Diverticulitis – Agency for Healthcare Research and Quality
Commentary on Twitter
The benefits of antibiotics in diverticulitis are uncertain with respect to complications, emergency✂️, recurrence, elective colonic resections&long‐term complications. This may be because diverticulitis is❌an infectious disorder, but an inflammatory onehttps://t.co/0HmAllw5Af
— John Damianos, M.D. (@john_damianosMD) June 26, 2022
2022 AHA/ACC key data elements and definitions for cardiovascular and noncardiovascular complications of COVID-19.
27 Jun, 2022 | 12:01h | UTCNews Release: New ACC/AHA Data Standards Address CV, Noncardiovascular Complications of COVID-19 – American College of Cardiology
Epidemiology of myocarditis and pericarditis following mRNA vaccination by vaccine product, schedule, and interdose interval among adolescents and adults in Ontario, Canada.
27 Jun, 2022 | 11:51h | UTCCommentary: Young Men’s Myocarditis Risk 5 Times Higher With Moderna vs Pfizer Vax — But Canadian study finds that 8-week interval before second dose attenuates some of the risk – MedPage Today (free registration required)
[Press Release – not published yet]: RCT: Sanofi-GSK report its vaccine targeted against ancestral and Beta strains had an overall efficacy of 72% against the Omicron variant.
27 Jun, 2022 | 11:52h | UTCPress Release: Sanofi-GSK first to report a successful efficacy study against Omicron with COVID-19 Beta-containing vaccine – Sanofi
Commentaries: Bivalent COVID Vax Gets Phase III Win Against Omicron, Companies Say — Sanofi, GSK boast of 72% efficacy against Omicron variant – MedPage Today (free registration required)
Use of pragmatic and explanatory trial designs in acute care research: lessons from COVID-19.
27 Jun, 2022 | 11:49h | UTC
Commentary on Twitter
NEW Personal View—Use of pragmatic and explanatory trial designs in acute care research: lessons from #COVID19
From Jonathan Casey & colleagues https://t.co/3vJs5j6Q1Q pic.twitter.com/hEUFYxNKRf
— The Lancet Respiratory Medicine (@LancetRespirMed) June 14, 2022
Perspective | What Omicron’s BA.4 and BA.5 variants mean for the pandemic.
27 Jun, 2022 | 11:48h | UTCWhat Omicron’s BA.4 and BA.5 variants mean for the pandemic – Nature
M-A: The role of resistance exercise training for improving cardiorespiratory fitness in healthy older adults.
27 Jun, 2022 | 11:42h | UTC
Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide.
27 Jun, 2022 | 11:46h | UTCNews Release: Vaccinations may have prevented almost 20 million COVID-19 deaths worldwide – Imperial College London
Original Study: Global impact of the first year of COVID-19 vaccination: a mathematical modelling study – The Lancet Infectious Diseases
Commentaries:
Covid-19 vaccines prevented nearly 20 million deaths in a year, study estimates – STAT
COVID-19 vaccines saved an estimated 20 million lives in 1 year – CIDRAP
Commentary on Twitter (thread – click for more)
🆕 @TheLancetInfDis
In the 1st year of Covid vaccinations, ~20 million deaths were prevented worldwide (data from 185 countries)
Another ~600,000 lives would have been saved if the @WHO 40% target been achievedhttps://t.co/BWig83xlnN @azraghani @imperialcollege @MRC_Outbreak pic.twitter.com/lF8biBJIlK— Eric Topol (@EricTopol) June 23, 2022
Cohort Study: The risk of stroke is substantially higher in the first year of initiation of oral contraceptives or hormone replacement therapy.
27 Jun, 2022 | 11:44h | UTCOral Contraceptives, Hormone Replacement Therapy, and Stroke Risk – Stroke (link to abstract – $ for full-text)
Commentary: Flash of Greater Stroke Risk at Initiation of Oral Contraceptives — Risk with hormone replacement therapy lingers in the long run, though – MedPage Today (free frustration required)
The 5th edition of the WHO classification of hematolymphoid tumors: myeloid and histiocytic/dendritic neoplasms.
27 Jun, 2022 | 11:40h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
Transcranial magnetic stimulation of the brain: What is stimulated? – A consensus and critical position paper.
27 Jun, 2022 | 11:36h | UTC
Commentary on Twitter
[Transcranial magnetic stimulation (TMS)] Siebner et al.: "Myelinated axon terminals of pyramidal cells and inhibitory interneurons in the crown of the gyri constitute low-threshold targets for TMS."https://t.co/1UfzuAHlPj@DRCMR_MRIhttps://t.co/LzHAzeGMZ5 https://t.co/n5hPOlFNlL pic.twitter.com/szdY77WieS
— IFCN and its Clinical Neurophysiology journals (@ClinicalNeuroph) May 21, 2022
The 5th edition of the WHO classification of hematolymphoid tumors: lymphoid neoplasms.
27 Jun, 2022 | 11:38h | UTCEditorial: The WHO Classification of Haematolymphoid Tumours – Leukemia
Review: Management of moderate-severe atopic dermatitis in pediatric age.
27 Jun, 2022 | 11:32h | UTC
Evaluation of prognostic risk models for postoperative pulmonary complications in adult patients undergoing major abdominal surgery: a systematic review and international external validation cohort study.
27 Jun, 2022 | 11:29h | UTC
Commentary on Twitter
https://twitter.com/STARSurgUK/status/1539596292812423169
Perspective: Measuring performance of the diagnostic process.
27 Jun, 2022 | 11:30h | UTCMeasuring Performance of the Diagnostic Process – JAMA (free for a limited period)
Consensus Statement: First-line PARP inhibitor maintenance for advanced, high-grade serous and endometrioid tubal, ovarian, and primary peritoneal cancers.
27 Jun, 2022 | 11:34h | UTC
Phase 2 single-arm study: Fazirsiran for liver disease associated with Alpha1-Antitrypsin deficiency.
27 Jun, 2022 | 11:19h | UTCFazirsiran for Liver Disease Associated with Alpha1-Antitrypsin Deficiency – New England Journal of Medicine (link to abstract – $ for full-text)
Commentary on Twitter
In this small trial in adults with ATT deficiency, fazirsiran was associated with a strong reduction of mutant AAT levels in the serum and liver and concurrent improvements in liver enzyme levels. #ILC2022 https://t.co/RibsKzOQfO pic.twitter.com/BnMcSyfVcq
— NEJM (@NEJM) June 25, 2022
Phase 2a RCT: Vaccine efficacy in adults in a respiratory syncytial virus challenge study.
27 Jun, 2022 | 11:21h | UTCVaccine Efficacy in Adults in a Respiratory Syncytial Virus Challenge Study -New England Journal of Medicine (link to abstract – $ for full-text)
Commentary: Challenge Study Shows Efficacy of RSV Vaccine in Healthy Adults – HealthDay
Commentary on Twitter
A human challenge model was used to assess the safety and immunogenicity of an RSV prefusion F protein-based vaccine against RSV infection. The vaccine construct has advanced to further clinical testing.https://t.co/KKfqzCyyGF pic.twitter.com/H7i7F8KLmv
— NEJM (@NEJM) June 22, 2022
Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019.
27 Jun, 2022 | 11:17h | UTCCommentary: Chronic Hepatitis B Infections Decreasing in Recent Years – HCP Live
Commentary on Twitter
New research from #GBDStudy – Global, regional, and national burden of hepatitis B, 1990–2019: a systematic analysis for the Global Burden of Disease Study 2019https://t.co/e0oxlT2gKd#hepB #HBV #nohep #livertwitter @IHME_UW pic.twitter.com/V8h1LrCoUQ
— The Lancet Gastroenterology & Hepatology (@LancetGastroHep) June 21, 2022
RCT: Efficacy of Ipilimumab vs. FOLFOX in combination with Nivolumab and Trastuzumab in patients with previously untreated ERBB2-positive esophagogastric adenocarcinoma.
27 Jun, 2022 | 11:11h | UTCEfficacy of Ipilimumab vs FOLFOX in Combination With Nivolumab and Trastuzumab in Patients With Previously Untreated ERBB2-Positive Esophagogastric Adenocarcinoma: The AIO INTEGA Randomized Clinical Trial – JAMA Oncology (free for a limited period)
Commentary: AIO INTEGA Provides Further Support for Immunotherapy in Patients With Advanced ERBB2-Positive Gastroesophageal Adenocarcinoma – JAMA Oncology (free for a limited period)
Systematic Review: Short‐acting inhaled bronchodilators for cystic fibrosis.
27 Jun, 2022 | 11:15h | UTCShort‐acting inhaled bronchodilators for cystic fibrosis – Cochrane Library
Summary: Short-acting inhaled bronchodilators for cystic fibrosis – Cochrane Library